Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies

Background: Wixela(®) Inhub(®) was developed to deliver inhaled fluticasone propionate/salmeterol (FP/S) combination as a substitutable generic equivalent to Advair(®) Diskus(®). These studies aimed to confirm the pharmacokinetic bioequivalence (BE) of FP/S after single doses of Wixela Inhub (test [...

Descripción completa

Detalles Bibliográficos
Autores principales: Haughie, Scott, Allan, Richard, Wood, Nolan, Ward, Jon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041328/
https://www.ncbi.nlm.nih.gov/pubmed/31364911
http://dx.doi.org/10.1089/jamp.2019.1537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041328/
https://www.ncbi.nlm.nih.gov/pubmed/31364911
http://dx.doi.org/10.1089/jamp.2019.1537

Ejemplares similares